Arno Therapeutics, Inc. ARNI

ARNI Company Overview

Arno Therapeutics, Inc. (formerly traded under the ticker ARNI) was a clinical-stage biopharmaceutical company focused on the development of targeted therapies for cancer and other serious diseases. The company operated within the biotechnology and oncology drug development industries, with its primary activities centered on identifying, licensing, and advancing small-molecule therapeutics through clinical development. Public disclosures and historical filings indicate that Arno’s lead development programs included oncology candidates targeting hormone-resistant and treatment-resistant cancers.

The company’s principal value drivers were its investigational drug pipeline and intellectual property portfolio rather than commercial product sales, as publicly available records do not indicate sustained revenue from marketed products. Arno Therapeutics evolved through licensing arrangements and development-stage acquisitions designed to build a focused oncology pipeline. Historical company materials indicate that its strategy emphasized precision medicine approaches and partnerships with academic and research institutions. Data regarding current operating status, ongoing commercial activity, and corporate continuity is inconclusive based on available public sources.